[Metabolic studies and therapeutic experiences with the beta-receptor blockader 4-(2-hydroxy-3-isopropylamino-propoxy)-indol (LB 46)].
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D050260:Carbohydrate Metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D005990:Glycerol / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007773:Lactates / Q000097:blood; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D013565:Sympatholytics / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D007211:Indoles; D007773:Lactates; D013565:Sympatholytics; D005990:Glycerol
Stoffwechseluntersuchungen und therapeutische Erfahrungen mit dem beta-Rezeptorenblocker 4-(2-hydroxy-3-isopropylamino-propoxy)-indol (LB 46.